Literature DB >> 4076322

Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days.

S Caccia, I Conforti, J Duchier, S Garattini.   

Abstract

The kinetics of accumulation and elimination of d- and l-fenfluramine (F) and norfenfluramine (NF) have been studied in 8 young healthy volunteers given daily doses of 60 mg of sugar-coated tablets of 20 mg dl-F hydrochloride (dl-F) t.i.d. and capsules of 15 mg d-F hydrochloride (d-F) b.i.d. for 15 days. Repeated doses of d-F plus l-F gave the same values for the parameters measured as did d-F administered alone. Steady-state concentrations of all compounds were achieved within 4-8 days. The predicted mean steady-state concentrations of d-F and elimination half-lives calculated from the results of a previous single dose study were similar to those measured at steady state in this study, confirming the lack of effect of the drug on hepatic microsomal enzymes and on kinetics after repeated dosing. d-NF concentrations were approximately half those of the parent drug and the half-life was almost twice as long. Steady state concentrations both of L-f and l-NF were consistently about 40-50% higher than of the d-isomers and there was a comparable in the half-life.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076322     DOI: 10.1007/BF00547426

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Gas-liquid chromatographic determination of the optical isomers of fenfluramine and norfenfluramine in biological samples.

Authors:  S Caccia; A Jori
Journal:  J Chromatogr       Date:  1977-11-21

2.  Cerebral metabolism of intraventricular [3H]-fenfluramine.

Authors:  A D Sherman; E M Gál
Journal:  Neuropharmacology       Date:  1977-05       Impact factor: 5.250

3.  Pharmacokinetics of absorption, distribution and elimination of fenfluramine and its main metabolite in man.

Authors:  A H Beckett; J A Salmon
Journal:  J Pharm Pharmacol       Date:  1972-02       Impact factor: 3.765

4.  The absorption and urinary excretion in man of fenfluramine and its main metabolite.

Authors:  A H Beckett; L G Brookes
Journal:  J Pharm Pharmacol       Date:  1967-12       Impact factor: 3.765

5.  Methamphetamine, fenfluramine and their N-dealkylated metabolites: effect on monoamine concentrations in rat tissues.

Authors:  C D Morgan; F Cattabeni; E Costa
Journal:  J Pharmacol Exp Ther       Date:  1972-01       Impact factor: 4.030

6.  Fenfluramine metabolism.

Authors:  R B Bruce; W R Maynard
Journal:  J Pharm Sci       Date:  1968-07       Impact factor: 3.534

7.  Plasma concentrations of fenfluramine and its metabolite, norfenfluramine, after single and repeated oral administration.

Authors:  D B Campbell; P Turner
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

8.  The identification of two new urinary metabolites of fenfluramine in man.

Authors:  K K Midha; E M Hawes; J K Cooper; J W Hubbard; K Bailey; I J McGilveray
Journal:  Xenobiotica       Date:  1983-01       Impact factor: 1.908

9.  Pharmacokinetics of fenfluramine enantiomers in man.

Authors:  S Caccia; M Ballabio; P De Ponte
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

10.  Species differences in the kinetics and metabolism of fenfluramine isomers.

Authors:  S Caccia; M Ballabio; G Guiso; M Rocchetti; S Garattini
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-07
View more
  10 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

2.  Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men.

Authors:  M Eriksson; U Berggren; C Fahlke; J Engel; J Balldin
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  Interactions of iprindole with fenfluramine metabolism in rat brain and liver.

Authors:  K M Hegadoren; G B Baker; R T Coutts; W G Dewhurst
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

Review 4.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  Effect of dexfenfluramine on sleep in healthy subjects.

Authors:  M Wiegand; S Bossert; R Kinney; K M Pirke; J C Krieg
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 7.  Serotonergic drugs and valvular heart disease.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250

8.  The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.

Authors:  G Cheymol; J Weissenburger; J M Poirier; C Gellee
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

9.  Fenfluramine-induced PVAT-dependent contraction depends on norepinephrine and not serotonin.

Authors:  Ramya K Kumar; Emma S Darios; Robert Burnett; Janice M Thompson; Stephanie W Watts
Journal:  Pharmacol Res       Date:  2018-09-03       Impact factor: 7.658

10.  Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Javier Garzón
Journal:  Oncotarget       Date:  2018-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.